RG1表位纳入HPV16L1-VLP不影响L1特异性免疫
候选泛HPV疫苗RG1-VLP由HPV16 L1 VLP携带L2的RG1表位构成。兔三剂免疫显示5μg RG1-VLP与Cervarix诱发的HPV16中和抗体滴度相当,25μg可广谱交叉中和高危HPV;小鼠两剂免疫联合18L1-VLP后HPV16中和滴度与Cervarix和Gardasil相似,并对hrHPV58阴道攻击有交叉保护。
要点
- 5μg RG1-VLP与Cervarix诱发的HPV16中和抗体滴度相当。
- 25μg RG1-VLP诱导针对多种hrHPV的交叉中和抗体。
- RG1-VLP联合18L1-VLP两剂免疫不损害L1特异性免疫。
核心结论
- RG1-VLP诱导的hrHPV16中和抗体与同剂量已上市疫苗相当,且即使与HPV18L1-VLP联合仍可交叉中和异源hrHPV。
研究设计与样本
- 兔(n=3)分别三次免疫1μg、5μg、25μg或125μg RG1-VLP或1/4剂Cervarix。
- 小鼠(n=10)两次免疫RG1-VLP(5μg)加18L1-VLP(5μg)。
主要发现
- 5μg RG1-VLP或16L1-VLP(Cervarix)诱导相当的HPV16衣壳反应性和中和抗体滴度(62,500/12,500-62,500或1000/10,000)。
- 25μg RG1-VLP诱导针对hrHPV18/31/33/45/52/58/26/70的强交叉中和滴度(50-1000)。
- 小鼠两次免疫后HPV16中和滴度(10,000)与Cervarix和Gardasil相似,并观察到针对hrHPV58阴道攻击的交叉保护。
临床怎么用
- RG1-VLP可作为泛HPV疫苗候选,与L1-VLP联合不损害L1特异性免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17-36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr) and cutaneous HPV. To compare RG1-VLP to licensed vaccines, rabbits (n = 3) were immunized thrice with 1 µg, 5 µg, 25 µg, or 125 µg of RG1-VLP or a 1/4 dose of Cervarix®. 5 µg of RG1-VLP or 16L1-VLP (Cervarix) induced comparable HPV16 capsid-reactive and neutralizing antibodies titers (62,500/12,500-62,500 or 1000/10,000). 25 µg RG1-VLP induced robust cross-neutralization titers (50-1000) against hrHPV18/31/33/45/52/58/26/70. To mimic reduced immunization schedules in adolescents, mice (n = 10) were immunized twice with RG1-VLP (5 µg) plus 18L1-VLP (5 µg). HPV16 neutralization (titers of 10,000) similar to Cervarix and Gardasil and cross-protection against hrHPV58 vaginal challenge was observed. RG1-VLP vaccination induces hrHPV16 neutralization comparable to similar doses of licensed vaccines, plus cross-neutralization to heterologous hrHPV even when combined with HPV18L1-VLP.
引用
- Schellenbacher C, Huber B, Skoll M, et al. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine. 2019. PMID: 31147274. doi:10.1016/j.vaccine.2019.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。